Naglazyme

Active Ingredient(s): Galsulfase
FDA Approved: * May 31, 2005
Pharm Company: * BIOMARIN
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Naglazyme Overview

Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body.[1] Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.[1] ERT is currently available for some lysosomal storage diseases: Gaucher disease, Fabry disease, MPS I, MPS II (Hunter syndrome), MPS VI and Pompe disease.[1] ERT does not correct the underlying genetic defect, b...

Read more Naglazyme Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Enzyme_replacement_therapy

Recent Naglazyme Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Naglazyme: (1 result)

Sorted by National Drug Code

• 68135-020 Naglazyme 5 mg/5ml Intravenous Solution by Biomarin Pharmaceutical Inc.

Other drugs which contain Galsulfase or a similar ingredient: (1 result)

• GALSULFASE